An Open-Label, Single-Arm, Phase Ii Clinical Trial Of Rp1, An Enhanced Potency Oncolytic Herpes Virus, Combined With Nivolumab In Four Solid Tumor Types: Initial Results From The Skin Cancer Cohorts.

e22050Background: RP1 is an oncolytic HSV that encodes a fusogenic GALV-GP R- protein and GM-CSF. RP1 demonstrated tolerable safety and tumor regression alone and with nivolumab (nivo) in ph 1 in p...